{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-385362","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-09-08T21:16:50+00:00","discovered_at":"2026-09-08T21:18:00.446762+00:00","generated_at":"2026-09-08T21:18:09.802775+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Perspective Therapeutics updates 212Pb pipeline presentation; highlights NET/melanoma/FAP data targeting $45B market","bullets":["Perspective Therapeutics updates corporate presentation for 212Pb radiopharma pipeline targeting a combined $45B+ solid tumor market.","VMT-α-NET (SSTR2+ NETs): Phase 1/2a ASCO 2026 data shows durable disease control across all doses; safety profile from n=68 treated patients.","VMT01 (melanoma/MC1R): preliminary anti-tumor activity at 3.0 mCi in Phase 1/2a; synergy with immune checkpoint inhibitors highlighted.","PSV359 (FAP-ɑ) shows improved tumor retention in Phase 1/2a solid tumors; CCK2R81 in medullary thyroid cancer; data expected across programs in 2026.","Platform supports direct-to-hospital delivery with regional 212Pb manufacturing and IP portfolio covering radiopharmaceutical value chain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-385362","json":"https://secwatch.observer/filing/0001193125-26-385362.json","markdown":"https://secwatch.observer/filing/0001193125-26-385362.md","text":"https://secwatch.observer/filing/0001193125-26-385362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526385362/0001193125-26-385362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526385362/catx-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T21:18:09.802775+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}